374 related articles for article (PubMed ID: 37085569)
1. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.
Mair MJ; Bartsch R; Le Rhun E; Berghoff AS; Brastianos PK; Cortes J; Gan HK; Lin NU; Lassman AB; Wen PY; Weller M; van den Bent M; Preusser M
Nat Rev Clin Oncol; 2023 Jun; 20(6):372-389. PubMed ID: 37085569
[TBL] [Abstract][Full Text] [Related]
2. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
Marin BM; Porath KA; Jain S; Kim M; Conage-Pough JE; Oh JH; Miller CL; Talele S; Kitange GJ; Tian S; Burgenske DM; Mladek AC; Gupta SK; Decker PA; McMinn MH; Stopka SA; Regan MS; He L; Carlson BL; Bakken K; Burns TC; Parney IF; Giannini C; Agar NYR; Eckel-Passow JE; Cochran JR; Elmquist WF; Vaubel RA; White FM; Sarkaria JN
Neuro Oncol; 2021 Dec; 23(12):2042-2053. PubMed ID: 34050676
[TBL] [Abstract][Full Text] [Related]
4. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
5. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
Gan HK; van den Bent M; Lassman AB; Reardon DA; Scott AM
Nat Rev Clin Oncol; 2017 Nov; 14(11):695-707. PubMed ID: 28675164
[TBL] [Abstract][Full Text] [Related]
6. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
7. Antibody drug conjugates for glioblastoma: current progress towards clinical use.
Gan HK; Parakh S; Osellame LD; Cher L; Uccellini A; Hafeez U; Menon S; Scott AM
Expert Opin Biol Ther; 2023; 23(11):1089-1102. PubMed ID: 37955063
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
9. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ
Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
[TBL] [Abstract][Full Text] [Related]
10. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress.
Rosner S; Valdivia A; Hoe HJ; Murray JC; Levy B; Felip E; Solomon BJ
Am Soc Clin Oncol Educ Book; 2023 May; 43():e389968. PubMed ID: 37163707
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
[TBL] [Abstract][Full Text] [Related]
13. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
Pramanik D
Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
[TBL] [Abstract][Full Text] [Related]
14. Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.
Anami Y; Otani Y; Xiong W; Ha SYY; Yamaguchi A; Rivera-Caraballo KA; Zhang N; An Z; Kaur B; Tsuchikama K
Cell Rep; 2022 May; 39(8):110839. PubMed ID: 35613589
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
17. Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond.
Barroso-Sousa R; Tolaney SM
BioDrugs; 2021 Mar; 35(2):159-174. PubMed ID: 33666903
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
19. Toxic warhead-armed antibody for targeted treatment of glioblastoma.
Xi J; Liu K; Peng Z; Dai X; Wang Y; Cai C; Yang D; Yan C; Li X
Crit Rev Oncol Hematol; 2024 Jan; 193():104205. PubMed ID: 38036153
[TBL] [Abstract][Full Text] [Related]
20. A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.
Vize CJ; Kim SK; Matthews T; Macsai M; Merrell R; Hsu S; Kundu MG; Yoon J; Kennedy E; Pai M; Bain E; Lassman AB; Moazami G
Ophthalmic Res; 2023; 66(1):1030-1043. PubMed ID: 37257422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
